NOT FOR DISTRIBUTION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. CALGARY, Alberta, May 08, 2025 (GLOBE NEWSWIRE) -- Alaris Equity Partners Income Trust (TSX-AD.UN) (together, as applicable, with its subsidiaries, “Alaris” or the "Trust") is pleased to announce its results for the three months ended March 31, 2025. The results are prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Stan ...

- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - - Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and PEGS, respectively - - Three INDs for wholly-owned programs anticipated in next 3 years, beginning with potential best-in-class Tissue Factor ADC, STRO-004, planned for 2H 2025 - - IND-enabling toxicology study ongoing for one program within Astellas iADC ...

Core Viewpoint - Theriva Biologics has successfully closed a public offering, raising approximately $7.5 million to support its cancer therapeutics development and other corporate purposes [1][2]. Group 1: Offering Details - The public offering consisted of 6,818,180 shares of common stock and warrants to purchase an equal number of shares at a combined price of $1.10 per share [1]. - The warrants are exercisable immediately and will expire five years from the issuance date [1]. - The offering was conducted under a registration statement that was declared effective by the SEC on May 7, 2025 [3]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily be used for working capital, general corporate purposes, research and development, and manufacturing scale-up [2]. - The company may also consider investing in or acquiring other products, businesses, or technologies, although no commitments currently exist [2]. Group 3: Company Overview - Theriva Biologics is a clinical-stage company focused on developing therapeutics for cancer and related diseases, with a particular emphasis on high unmet medical needs [5]. - The company's lead candidates include VCN-01, SYN-004, and SYN-020, targeting various aspects of cancer treatment and gastrointestinal health [5].

PITTSBURGH, May 08, 2025 (GLOBE NEWSWIRE) -- Montauk Renewables, Inc. (“Montauk” or “the Company”) (NASDAQ: MNTK), a renewable energy company specializing in the management, recovery, and conversion of biogas into renewable natural gas (“RNG”), today announced financial results for the first quarter ended March 31, 2025. First Quarter Highlights: • Revenues of $42.6 million, increased 9.8% compared to the first quarter of 2024 • Net loss of $0.5 million, compared to net income of $1.9 million for the firs ...

MELVILLE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its first quarter 2025 financial results after market close on Wednesday, May 14, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update. Fir ...

BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended March 31, 2025. “During the first quarter, we continued to advance GB3226, our dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML,” said Dr. Hans Schambye, CEO of Galecto. “We continued preclinical studies to support our planned IND su ...

Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone) KANSAS CITY, Kan., May 08, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results f ...

ISTANBUL, May 08, 2025 (GLOBE NEWSWIRE) -- D-MARKET Electronic Services & Trading (d/b/a “Hepsiburada”) (NASDAQ: HEPS), a leading Turkish e-commerce platform (referred to herein as “Hepsiburada” or the “Company”), today announces its unaudited financial results for the first quarter ended March 31, 2025. Restatement of financial information: Pursuant to the International Accounting Standard 29, Financial Reporting in Hyperinflationary Economies (“IAS 29”), the financial statements of entities whose function ...

MISSISSAUGA, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2025 on Thursday, May 15, 2025 after market hours. A presentation on the Company’s first quarter 2025 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent ...

On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson’s disease in Q4 2025Strengthened balance sheet with recent financingAdvancing innovative POZ Platform across multiple therapeutic modalitiesTwo new seasoned biotech leaders added to the Board of Directors HUNTSVILLE, May 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, ...